Anzeige
Mehr »
Mittwoch, 12.08.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWA4 | ISIN: GB00BMCLYF79 | Ticker-Symbol: 88Q
Xetra
11.08.26 | 17:35
5,800 Euro
+5,45 % +0,300
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
4BASEBIO PLC Chart 1 Jahr
5-Tage-Chart
4BASEBIO PLC 5-Tage-Chart
RealtimeGeldBriefZeit
5,1507,20011.08.
Xetra-Umsätze heute
UhrzeitAktienkursStück

Keine Umsätze verfügbar.

Tagesumsatz Xetra+0,300
+5,45 %

0

 Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.

Aktuelle News zur Aktie 4BASEBIO PLC

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
22.07.4basebio Plc - Grant of Options & Director/PDMR Dealing3664basebio Plc - Grant of Options & Director/PDMR Dealing PR Newswire LONDON, United Kingdom, July 22 4basebio PLC ("4basebio"...
► Artikel lesen
08.07.4basebio Plc - Director Appointment5814basebio Plc - Director Appointment PR Newswire LONDON, United Kingdom, July 08 4basebio PLC ("4basebio" or the "Company") ...
► Artikel lesen
30.06.4basebio Plc - Result of AGM & Issue of Options4164basebio Plc - Result of AGM & Issue of Options PR Newswire LONDON, United Kingdom, June 30 4basebio PLC ("4basebio"...
► Artikel lesen
4BASEBIO Aktie jetzt für 0€ handeln
16.06.4basebio Plc - Notice of Investor Presentation4064basebio Plc - Notice of Investor Presentation PR Newswire LONDON, United Kingdom, June 16 4basebio...
► Artikel lesen
15.06.IN BRIEF: 4basebio appoints Jeff Coller to Strategic Advisory Board1
Weiter >>
39 Nachrichten in den letzten 12 Monaten
Das könnte Sie auch interessieren
ZeitAktuelle NachrichtenMedien
DiVor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateEnrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of...
► Artikel lesen
DiMicrobot Medical Inc.: Microbot Medical Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second QuarterRevenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market...
► Artikel lesen
DiPDS Biotechnology Corporation: PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on developing targeted...
► Artikel lesen
DiClearmind Medicine Inc.: Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug DeliveryVancouver, Canada, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and...
► Artikel lesen
DiArch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United StatesTORONTO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that the Company will expand its ongoing Phase II trial of LSALT peptide targeting...
► Artikel lesen